Loeb Partners Corp’s Regeneron Pharmaceuticals REGN Stock Holding History

Loeb Partners Corp’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,500	Closed	-$564K	–	142
2017 Q4	$564K	Buy	+1,500	New	+$607K	0.17%	104

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Loeb Partners Corp's REGN Position: Q1 2018 in Review

Loeb Partners Corp sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 1,500 shares — an estimated $564K sold.

Loeb Partners Corp first reported a position in REGN in Q4 2017 and held it in 1 quarter. The position peaked at $564K in Q4 2017. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

Loeb Partners Corp reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Loeb Partners Corp sold 1,500 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $564K.
Loeb Partners Corp first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 1 quarter.
Loeb Partners Corp's Regeneron Pharmaceuticals position peaked at $564K in Q4 2017.
619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Loeb Partners Corp's 13F filing for Q1 2018, filed 14 May 2018.